WILLIAM WONG to Ontario
This is a "connection" page, showing publications WILLIAM WONG has written about Ontario.
Connection Strength
2.126
-
Health Utilities in People with Hepatitis C Virus Infection: A Study Using Real-World Population-Level Data. Med Decis Making. 2025 Apr; 45(3):332-343.
Score: 0.232
-
Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada. Curr Oncol. 2024 Dec 27; 32(1).
Score: 0.230
-
Impact of new direct-acting antiviral therapy on the prevalence and undiagnosed proportion of chronic hepatitis C infection. Liver Int. 2024 Jun; 44(6):1383-1395.
Score: 0.217
-
Cost-utility analysis of a multispecialty interprofessional team dementia care model in Ontario, Canada. BMJ Open. 2023 04 19; 13(4):e064882.
Score: 0.204
-
Cost Effectiveness of Implementing a Universal Birth Hepatitis B Vaccination Program in Ontario. Pharmacoeconomics. 2023 04; 41(4):413-425.
Score: 0.201
-
Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study. CMAJ Open. 2021 Jan-Mar; 9(1):E167-E174.
Score: 0.176
-
Estimating chronic hepatitis C prevalence in British Columbia and Ontario, Canada, using population-based cohort studies. J Viral Hepat. 2020 12; 27(12):1419-1429.
Score: 0.171
-
Cost effectiveness of in vitro fertilisation and preimplantation genetic testing to prevent transmission of BRCA1/2 mutations. Hum Reprod. 2020 02 29; 35(2):434-445.
Score: 0.164
-
Real-world healthcare costs for patients treated with chimeric antigen receptor T-cell therapy in Canada. Leuk Lymphoma. 2025 Oct; 66(10):1875-1883.
Score: 0.059
-
Bridging Hepatitis C Care Gaps: A Modeling Approach for Achieving the WHO's Targets in Ontario, Canada. Viruses. 2024 07 31; 16(8).
Score: 0.056
-
Hepatitis C Attributable Healthcare Costs and Mortality among Immigrants: A Population-Based Matched Cohort Study. Can J Gastroenterol Hepatol. 2024; 2024:5573068.
Score: 0.054
-
An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada. Pharmacoeconomics. 2024 Apr; 42(4):393-407.
Score: 0.054
-
Characterizing the cascade of care for hepatitis C virus infection among Status First Nations peoples in Ontario: a retrospective cohort study. CMAJ. 2023 04 11; 195(14):E499-E512.
Score: 0.051
-
Initial health care costs for COVID-19 in British Columbia and Ontario, Canada: an interprovincial population-based cohort study. CMAJ Open. 2022 Jul-Sep; 10(3):E818-E830.
Score: 0.049
-
"Bring the Hoses to Where the Fire Is!": Differential Impacts of Marginalization and Socioeconomic Status on COVID-19 Case Counts and Healthcare Costs. Value Health. 2022 08; 25(8):1307-1316.
Score: 0.048
-
Health care costs associated with hepatitis C virus infection in First Nations populations in Ontario: a retrospective matched cohort study. CMAJ Open. 2021 Jul-Sep; 9(3):E897-E906.
Score: 0.046
-
Hepatitis C virus infection in First Nations populations in Ontario from 2006 to 2014: a population-based retrospective cohort analysis. CMAJ Open. 2021 Jul-Sep; 9(3):E886-E896.
Score: 0.046
-
Population-based estimate of hepatitis C virus prevalence in Ontario, Canada. PLoS One. 2018; 13(1):e0191184.
Score: 0.036
-
The cost-utility of integrated cervical cancer prevention strategies in the Ontario setting - Can we do better? Vaccine. 2016 Apr 07; 34(16):1936-44.
Score: 0.031